Glycyrrhizin inhibits the manifestations of anti-inflammatory responses that appear in association with systemic inflammatory response syndrome (SIRS)-like reactions

Cytokine

Volumn 35, Issue 5-6, 2006, Pages 295-301

  Takei, Miwa ^a   Kobayashi, Makiko ^a,b   Herndon, David N ^b   Pollard, Richard B ^c   Suzuki, Fujio ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CCL2; Glycyrrhizin; IL 4; Neutrophils; Systemic inflammatory response syndrome

Indexed keywords

GLYCYRRHIZIC ACID; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY RESPONSE SYNDROME; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE CULTURE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BURNS; CELLS, CULTURED; CHEMOKINE CCL2; COCULTURE TECHNIQUES; GLYCYRRHIZIC ACID; HUMANS; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; PANCREATITIS; SPLEEN; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

MURINAE;

EID: 37849189180     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.10.002     Document Type: Article

References (40)

1. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., Schein R.M., and Sibbald W.J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101 (1992) 1644-1655
2. Bellingan G. Inflammatory cell activation in sepsis. Br Med Bull 55 (1999) 12-29
3. Bone R.C. Immunological dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 125 (1996) 680-687
4. Bone R.C. Systemic inflammatory response syndrome: a unifying concept of systemic inflammation. In: Fein A.M., Abraham E.M., Balk R.A., Bernard G.R., Bone R.C., Dantzker D.R., and Fink M.P. (Eds). Sepsis and Multiorgan failure (1997), Williams & Wilkins 3-10
5. Foex B.A. Systemic responses to trauma. Br Med Bull 55 (1999) 726-743
6. Bone R.C. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24 (1996) 1125-1128
7. Kox W.J., Bone R.C., Krausch D., Docke W.D., Kox S.N., Wauer H., Egerer K., Querner S., Asadullah K., von Baehr R., and Volk H.D. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 157 (1997) 389-393
8. Docke W.D., Randow F., Syrbe U., Krausch D., Asadullah K., Reinke P., Volk H.D., and Kox W. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med 3 (1997) 678-681
9. Volk H.D., Reinke P., and Docke W.D. Clinical aspects: from systemic inflammation to "immunoparalysis". Chem Immunol 74 (2000) 162-177
10. Takahashi H., Tsuda Y., Takeuchi D., Kobayashi M., Herndon D.N., and Suzuki F. Influence of systemic inflammatory response syndrome on host resistance against bacterial infections. Crit Care Med 32 (2004) 1879-1885
11. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg 175 (1998) 76-83
12. Tsuda Y., Takahashi H., Kobayashi M., Hanafusa T., Herndon D.N., and Suzuki F. CCL2, a product of mice early after systemic inflammatory response syndrome (SIRS), induces alternatively activated macrophages capable of impairing antibacterial resistance of SIRS mice. J Leukoc Biol 76 (2004) 368-373
13. Suzuki H., Ohta Y., Takino T., Fujisawa K., and Hirayama C. Effects of glycyrrhizin on biomedical tests in patients with chronic hepatitis-double blind trial. Asian Med J 26 (1983) 423-438
14. van Rossum T.G., Vulto A.G., de Man R.A., Brouwer J.T., and Schalm S.W. Glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 12 (1998) 199-205
15. Numazaki K., Nagata N., Sato T., and Chiba S. Effect of glycyrrhizin, cyclosporin A, and tumor necrosis factor α on infection of U-937 and MRC-5 cells by human cytomegalovirus. J Leukoc Biol 55 (1994) 24-28
16. Pompei R., Flore O., Marccialis M.A., Pani A., and Loddo B. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature 281 (1979) 689-690
17. Utsunomiya T., Kobayashi M., Pollard R.B., and Suzuki F. Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus. Antimicrob Agents Chemother 41 (1997) 551-556
18. Ito M., Sato A., Hirabayashi K., Tanabe F., Shigeta S., Baba M., De Clercq E., Nakashima H., and Yamamoto N. Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV). Antiviral Res 10 (1988) 289-298
19. Mori K., Sakai H., Suzuki S., Sugai K., Akutsu Y., Ishikawa M., Seino Y., Ishida N., Uchida T., Kariyone S., Endo Y., and Miura A. Effect of glycyrrhizin (SNMC: Stronger Neo-Minophagen C) in hemophilia patients with HIV infection. Tohoku J Exp Med 158 (1989) 25-35
20. Sasaki H., Takei M., Kobayashi M., Pollard R.B., and Suzuki F. Effect of glycyrrhizin, an active component of licorice roots, on HIV replication in cultures of peripheral blood mononuclear cells from HIV sero(+) patients. Pathobiology 70 (2002) 229-236
21. Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., and Doerr H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361 (2003) 2045-2046
22. Takei M., Kobayashi M., Li X.D., Pollard R.B., and Suzuki F. Glycyrrhizin inhibits R5 HIV replication in peripheral blood monocytes treated with 1-methyladenosine. Pathobiology 72 (2005) 117-123
23. Kobayashi H., Kobayashi M., Utsunomiya T., Herndon D.N., Pollard R.B., and Suzuki F. Therapeutic protective effects of IL-12 combined with soluble IL-4 receptor against established infections of herpes simplex virus type 1 in thermally injured mice. J Immunol 162 (1999) 7148-7154
24. Tsuda Y., Takahashi H., Kobayashi M., Hanafusa T., Herndon D.N., and Suzuki F. Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity 21 (2004) 215-226
25. Shinada M., Azuma M., Kawai H., Sazaki K., Yoshida I., Yoshida T., Suzutani T., and Sakuma T. Enhancement of interferon-γ production in glycyrrhizin-treated human peripheral lymphocytes in response to concanavalin A and to surface antigen of hepatitis B virus. Proc Soc Exp Biol Med 181 (1986) 205-210
26. Zhang Y.H., Yoshida T., Isobe K., Rahman S.M., Nagase F., Ding L., and Nakashima I. Modulation by glycyrrhizin of the cell-surface expression of H-2 class I antigens on murine tumour cell lines and normal cell populations. Immunology 70 (1990) 405-410
27. Zhang Y.H., Isobe K., Nagase F., Lwin T., Kato M., Hamaguchi M., Yokochi T., and Nakashima I. Glycyrrhizin as a promoter of the late signal transduction for interleukin-2 production by splenic lymphocytes. Immunology 79 (1993) 528-534
28. Shimizu T., Shiratori K., Sawada T., Kobayashi M., Hayashi N., Saotome H., and Keith J.C. Recombinant human interleukin-11 decreases severity of acute necrotizing pancreatitis in mice. Pancreas 21 (2000) 134-140
29. Furukawa K., Kobayashi M., Herndon D.N., Pollard R.B., and Suzuki F. Appearance of monocyte chemoattractant protein 1 (MCP-1) early after thermal injury: role in the subsequent development of burn-associated type 2 T-cell responses. Ann Surg 236 (2002) 112-119
30. Takahashi H., Kobayashi M., Tsuda Y., Sanford A.P., Herndon D.N., and Suzuki F. CCL2 as a trigger of manifestations of compensatory anti-inflammatory response syndrome in mice with severe systemic inflammatory response syndrome. J Leukoc Biol 79 (2005) 789-796
31. Mukaida N., Zachariae C.C., Gusella G.L., and Matsushima K. Dexamethasone inhibits the induction of monocyte chemotactic-activating factor production by IL-1 or tumor necrosis factor. J Immunol 146 (1991) 1212-1215
32. Kelly R.W., Carr G.G., and Riley S.C. The inhibition of synthesis of a β-chemokine, monocyte chemotactic protein-1 (MCP-1) by progesterone. Biochem Biophys Res Commun 239 (1997) 557-561
33. Frazier-Jessen M.R., and Kovacs E.J. Estrogen modulation of JE/monocyte chemoattractant protein-1 mRNA expression in murine macrophages. J Immunol 154 (1995) 1838-1845
34. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu Rev Immunol 20 (2002) 197-216
35. O'Shea J.J., Gadina M., and Schreiber R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 (2002) S121-S131
36. Seder R.A., and Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature 406 (2000) 793-798
37. Goerdt S., and Orfanos C.E. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 10 (1999) 137-142
38. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 3 (2003) 23-35
39. Takahashi H., Tashiro T., Miyazaki M., Kobayashi M., Pollard R.B., and Suzuki F. An essential role of macrophage inflammatory protein 1α/CCL3 on the expression of host's innate immunities against infectious complications. J Leukoc Biol 72 (2002) 1190-1197
40. Hamilton T.A., Ohmori Y., and Tebo J. Regulation of chemokine expression by anti-inflammatory cytokines. Immunol Res 25 (2002) 229-245